IFNA5

Summary

IFNA5 (interferon alpha 5, HGNC:5426) is a protein-coding gene on chromosome 9p21.3, encoding Interferon alpha-5 (P01569). Produced by macrophages, IFN-alpha have antiviral activities.

Predicted to enable cytokine activity and type I interferon receptor binding activity. Predicted to be involved in several processes, including lymphocyte activation involved in immune response; response to exogenous dsRNA; and type I interferon-mediated signaling pathway. Predicted to be located in extracellular region. Predicted to be active in extracellular space.

Source: NCBI Gene 3442 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 34 total
• Druggable target: yes
• MANE Select transcript: NM_002169

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:5426
Approved symbol	IFNA5
Name	interferon alpha 5
Location	9p21.3
Locus type	gene with protein product
Status	Approved
Aliases	IFN-alphaG
Ensembl gene	ENSG00000147873
Ensembl biotype	protein_coding
OMIM	147565
Entrez	3442

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000610521

RefSeq mRNA: 1 — MANE Select: NM_002169 NM_002169

CCDS: CCDS6502

Canonical transcript exons

ENST00000610521 — 1 exons

Exon	Start	End
ENSE00003724856	21304326	21305313

Expression profiles

Bgee: expression breadth broad, 23 present calls, max score 56.55.

Top tissues by expression

203 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
decidua	UBERON:0002450	56.55	gold quality
ileal mucosa	UBERON:0000331	55.84	gold quality
hair follicle	UBERON:0002073	52.83	gold quality
pancreatic ductal cell	CL:0002079	52.30	silver quality
frontal pole	UBERON:0002795	50.41	gold quality
quadriceps femoris	UBERON:0001377	50.30	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
epithelial cell of pancreas	CL:0000083	49.86	gold quality
metanephric glomerulus	UBERON:0004736	49.61	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
vastus lateralis	UBERON:0001379	49.17	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality
myocardium	UBERON:0002349	48.87	gold quality
type B pancreatic cell	CL:0000169	48.83	gold quality
oviduct epithelium	UBERON:0004804	48.76	gold quality
cardiac muscle of right atrium	UBERON:0003379	48.55	gold quality
CA1 field of hippocampus	UBERON:0003881	48.50	gold quality
thymus	UBERON:0002370	48.43	gold quality
left ventricle myocardium	UBERON:0006566	48.24	gold quality
orbitofrontal cortex	UBERON:0004167	48.20	gold quality
kidney epithelium	UBERON:0004819	48.11	gold quality
upper arm skin	UBERON:0004263	48.06	gold quality
cervix epithelium	UBERON:0004801	48.04	gold quality
tongue squamous epithelium	UBERON:0006919	47.92	gold quality
mucosa of urinary bladder	UBERON:0001259	47.80	gold quality
nephron tubule	UBERON:0001231	47.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.48

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): IRF3, IRF5, IRF7, IRF8, PITX1

Literature-anchored findings (GeneRIF, showing 2)

• This is the first report of positive association of IFNA gene in SLE, especially the role of specific subtypes IFNA1 and IFNA5. (PMID:19000144)
• Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. (PMID:8668211)

Cross-species orthologs

34 orthologs

Organism	Symbol	Gene ID
danio_rerio	ifnphi2	ENSDARG00000069012
danio_rerio	ifnphi3	ENSDARG00000070676
mus_musculus	Ifna13	ENSMUSG00000063376
mus_musculus	Ifna4	ENSMUSG00000070904
mus_musculus	Ifna12	ENSMUSG00000073811
mus_musculus	Ifna2	ENSMUSG00000078354
mus_musculus	Ifna16	ENSMUSG00000078355
mus_musculus	Ifna9	ENSMUSG00000095270
mus_musculus	Ifna1	ENSMUSG00000095498
mus_musculus	Ifna14	ENSMUSG00000095896
mus_musculus	Ifna15	ENSMUSG00000096011
mus_musculus	Ifna5	ENSMUSG00000096682
mus_musculus	Ifnab	ENSMUSG00000100079
mus_musculus	Ifna11	ENSMUSG00000100549
mus_musculus	Ifna7	ENSMUSG00000100713
mus_musculus	Ifna6	ENSMUSG00000101252
rattus_norvegicus		ENSRNOG00000071845
rattus_norvegicus	Ifna12l	ENSRNOG00000072681
rattus_norvegicus	Ifna16l1	ENSRNOG00000074841
rattus_norvegicus		ENSRNOG00000075722
rattus_norvegicus		ENSRNOG00000076372
rattus_norvegicus	Ifna4	ENSRNOG00000077072
rattus_norvegicus	Ifna2	ENSRNOG00000078310
rattus_norvegicus	Ifna5	ENSRNOG00000079725
rattus_norvegicus	Ifna1l1	ENSRNOG00000079800
rattus_norvegicus		ENSRNOG00000079804
rattus_norvegicus		ENSRNOG00000081823
rattus_norvegicus		ENSRNOG00000082441
rattus_norvegicus		ENSRNOG00000082845
rattus_norvegicus		ENSRNOG00000083047
rattus_norvegicus	Ifna1	ENSRNOG00000084770
rattus_norvegicus		ENSRNOG00000085373
rattus_norvegicus		ENSRNOG00000085882
rattus_norvegicus		ENSRNOG00000086565

Paralogs (16): IFNA6 (ENSG00000120235), IFNA8 (ENSG00000120242), IFNA21 (ENSG00000137080), IFNA16 (ENSG00000147885), IFNK (ENSG00000147896), IFNB1 (ENSG00000171855), IFNW1 (ENSG00000177047), IFNE (ENSG00000184995), IFNA10 (ENSG00000186803), IFNA2 (ENSG00000188379), IFNA1 (ENSG00000197919), IFNA7 (ENSG00000214042), IFNA14 (ENSG00000228083), IFNA13 (ENSG00000233816), IFNA17 (ENSG00000234829), IFNA4 (ENSG00000236637)

Protein

Protein identifiers

Interferon alpha-5 — P01569 (reviewed: P01569)

Alternative names: Interferon alpha-61, Interferon alpha-G

All UniProt accessions (2): P01569, A0A7R8C382

UniProt curated annotations — full annotation on UniProt →

Function. Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.

Subcellular location. Secreted.

Similarity. Belongs to the type-I (or alpha/beta) interferon family.

RefSeq proteins (1): NP_002160* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000471	Interferon_alpha/beta/delta	Family
IPR009079	4_helix_cytokine-like_core	Homologous_superfamily

Pfam: PF00143

UniProt features (4 total): disulfide bond 2, signal peptide 1, chain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P01569-F1	88.12	0.62

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 24–122, 52–162

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-909733	Interferon alpha/beta signaling
R-HSA-912694	Regulation of IFNA/IFNB signaling
R-HSA-933541	TRAF6 mediated IRF7 activation
R-HSA-9705671	SARS-CoV-2 activates/modulates innate and adaptive immune responses
R-HSA-983231	Factors involved in megakaryocyte development and platelet production
R-HSA-9833109	Evasion by RSV of host interferon responses

MSigDB gene sets: 120 (showing top): REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA, BROWNE_HCMV_INFECTION_4HR_UP, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_CELLULAR_RESPONSE_TO_VIRUS, REACTOME_INNATE_IMMUNE_SYSTEM, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_RESPONSE_TO_PEPTIDE, GOBP_B_CELL_ACTIVATION, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_RESPONSE_TO_TYPE_I_INTERFERON, BROWNE_HCMV_INFECTION_16HR_UP, KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY, GOBP_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, BLALOCK_ALZHEIMERS_DISEASE_UP

GO Biological Process (11): adaptive immune response (GO:0002250), T cell activation involved in immune response (GO:0002286), B cell activation involved in immune response (GO:0002312), natural killer cell activation involved in immune response (GO:0002323), humoral immune response (GO:0006959), response to exogenous dsRNA (GO:0043330), defense response to virus (GO:0051607), type I interferon-mediated signaling pathway (GO:0060337), cellular response to virus (GO:0098586), defense response (GO:0006952), signal transduction (GO:0007165)

GO Molecular Function (3): cytokine activity (GO:0005125), cytokine receptor binding (GO:0005126), type I interferon receptor binding (GO:0005132)

GO Cellular Component (2): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Interferon Signaling	1
Interferon alpha/beta signaling	1
DDX58/IFIH1-mediated induction of interferon-alpha/beta	1
SARS-CoV-2-host interactions	1
Hemostasis	1
RSV-host interactions	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
immune response	4
lymphocyte activation involved in immune response	3
response to virus	2
T cell activation	1
B cell activation	1
natural killer cell activation	1
innate immune response	1
response to dsRNA	1
defense response	1
cellular response to type I interferon	1
interferon-mediated signaling pathway	1
response to stress	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
signaling receptor binding	1
cytokine receptor binding	1
protein-containing complex binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1370 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IFNA5	IL2	P01585	855
IFNA5	IFNG	P01579	762
IFNA5	IFNAR1	P17181	750
IFNA5	ISG15	P05161	678
IFNA5	CR2	P20023	668
IFNA5	IFNL3	Q8IZI9	668
IFNA5	IL6	P05231	662
IFNA5	IRF8	Q02556	645
IFNA5	TLR3	O15455	642
IFNA5	MX1	P20591	632
IFNA5	ABL1	P00519	624
IFNA5	GPT	P24298	624
IFNA5	CD4	P01730	621
IFNA5	TNF	P01375	609
IFNA5	MX2	P20592	596

IntAct

6 interactions, top by confidence:

A	B	Type	Score
IFNA2	IFIT3	psi-mi:“MI:0914”(association)	0.530
IFNA5	IFNA13	psi-mi:“MI:0914”(association)	0.530
IFNA5	LGALS9	psi-mi:“MI:0914”(association)	0.350

BioGRID (40): IFNA5 (Affinity Capture-MS), UBR3 (Affinity Capture-MS), IFNA13 (Affinity Capture-MS), IFNA14 (Affinity Capture-MS), IFNA17 (Affinity Capture-MS), IFNA6 (Affinity Capture-MS), IFNA4 (Affinity Capture-MS), ADAMTS1 (Affinity Capture-MS), IFIT3 (Affinity Capture-MS), CLU (Affinity Capture-MS), SURF1 (Affinity Capture-MS), ISG15 (Affinity Capture-MS), IFI44L (Affinity Capture-MS), IFIT1 (Affinity Capture-MS), IFNA6 (Affinity Capture-MS)

ESM2 similar proteins: O46633, P01562, P01563, P01566, P01567, P01568, P01569, P01570, P01571, P01572, P05000, P05002, P05003, P05004, P05005, P05006, P05007, P05008, P05009, P05010, P05013, P05014, P05015, P07348, P07349, P07352, P09235, P15696, P28169, P28171, P28172, P32881, P49876, P49877, P49878, P49879, P56828, P56829, P56830, P56831

Diamond homologs: A7UHZ5, O46633, O77812, O97945, P01562, P01563, P01566, P01567, P01568, P01569, P01570, P01571, P01572, P01573, P01574, P01575, P01576, P01577, P01578, P05000, P05001, P05002, P05003, P05004, P05005, P05006, P05007, P05008, P05009, P05010, P05011, P05012, P05013, P05014, P05015, P06799, P07348, P07349, P07350, P07351

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

34 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

254 predictions. Top by Δscore:

Variant	Effect	Δscore
9:21305151:T:TA	donor_gain	0.7600
9:21304973:T:TA	donor_gain	0.6900
9:21304505:T:C	donor_gain	0.6500
9:21304549:A:C	donor_gain	0.6500
9:21304954:ATC:A	donor_gain	0.6100
9:21304954:AT:A	donor_gain	0.5900
9:21304955:T:TA	donor_gain	0.5900
9:21304626:A:C	donor_gain	0.5800
9:21304547:TAAC:T	donor_gain	0.5700
9:21304548:AACA:A	donor_gain	0.5700
9:21304548:A:AC	donor_gain	0.5600
9:21304892:CAGG:C	donor_gain	0.5600
9:21304898:T:TA	donor_gain	0.5600
9:21305209:G:A	donor_gain	0.5600
9:21304876:A:T	donor_gain	0.5500
9:21304880:T:TA	donor_gain	0.5500
9:21305012:T:TG	acceptor_gain	0.5500
9:21304546:TTAA:T	donor_gain	0.5400
9:21304581:A:C	donor_gain	0.5400
9:21304614:TGAA:T	donor_gain	0.5400
9:21304521:C:A	donor_gain	0.5300
9:21304631:A:C	donor_gain	0.5200
9:21304911:G:C	donor_gain	0.5200
9:21304956:C:A	donor_gain	0.5200
9:21304829:ACAGT:A	donor_gain	0.5100
9:21304830:CA:C	donor_gain	0.5100
9:21304830:CAGTC:C	donor_gain	0.5100
9:21304845:C:CT	donor_gain	0.5100
9:21304955:T:C	donor_gain	0.5100
9:21305122:T:TA	donor_gain	0.5100

AlphaMissense

1256 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:21304816:A:C	F147L	0.939
9:21304816:A:T	F147L	0.939
9:21304818:A:G	F147L	0.939
9:21305080:A:C	F59L	0.907
9:21305080:A:T	F59L	0.907
9:21305082:A:G	F59L	0.907
9:21304765:C:A	W164C	0.866
9:21304765:C:G	W164C	0.866
9:21304984:G:C	F91L	0.817
9:21304984:G:T	F91L	0.817
9:21304986:A:G	F91L	0.817
9:21304910:A:G	L116P	0.760
9:21304957:C:A	W100C	0.755
9:21304957:C:G	W100C	0.755
9:21304820:T:G	Y146S	0.750
9:21304817:A:G	F147S	0.748
9:21304757:A:T	V167D	0.741
9:21304753:T:A	R168S	0.719
9:21304753:T:G	R168S	0.719
9:21304796:A:G	L154P	0.716
9:21304769:G:T	A163E	0.715
9:21305081:A:C	F59C	0.714
9:21304767:A:G	W164R	0.709
9:21304767:A:T	W164R	0.709
9:21305101:G:C	C52W	0.707
9:21304821:A:G	Y146H	0.703
9:21304800:A:C	Y153D	0.701
9:21304771:A:C	C162W	0.699
9:21304817:A:C	F147C	0.699
9:21304820:T:C	Y146C	0.698

dbSNP variants (sampled 300 via entrez): RS1000359945 (9:21306843 A>G), RS1000372993 (9:21306675 C>G,T), RS1000719546 (9:21304317 T>A), RS1001910319 (9:21306145 G>A,T), RS1001920143 (9:21305905 TATTAAA>T), RS1002681418 (9:21306553 G>A), RS1002697699 (9:21303885 T>C), RS1003924980 (9:21306419 G>A), RS1006823156 (9:21307166 G>A), RS1007587546 (9:21306780 A>C,G), RS1008217099 (9:21304826 C>G,T), RS1008274474 (9:21305492 C>T), RS1009037732 (9:21304359 G>A), RS1009051844 (9:21304131 G>A,C,T), RS1009975982 (9:21306560 G>A)

Disease associations

OMIM: gene MIM:147565 | disease phenotypes: MIM:303350

GenCC curated gene-disease

Mondo (1): hereditary spastic paraplegia (MONDO:0019064)

Orphanet (1): Hereditary spastic paraplegia (Orphanet:685)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D015419	Spastic Paraplegia, Hereditary	C10.500.300.820; C10.574.500.495.820; C10.668.829.800.300.820; C16.131.666.300.820; C16.320.400.375.820

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3856161 (PROTEIN FAMILY)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
apocarotenal	increases expression	1
bisphenol A	increases methylation	1
gardiquimod	decreases reaction, increases expression	1
theaflavin-3,3’-digallate	affects expression	1
Folic Acid	decreases expression	1
beta Carotene	increases expression	1
Protein Kinase Inhibitors	decreases reaction, increases expression	1

Clinical trials (associated diseases)

51 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT07542548	PHASE4	COMPLETED	D-Cycloserine for Serine Palmitoyltransferase Inhibition
NCT03961906	PHASE2	COMPLETED	Physiotherapy in Hereditary Spastic Paraplegia
NCT04768166	PHASE2	COMPLETED	Testing Miglustat Administration in Subjects With Spastic Paraplegia 11
NCT06117020	PHASE1	COMPLETED	Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
NCT02604186	PHASE2/PHASE3	COMPLETED	Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia
NCT05518188	PHASE1/PHASE2	RECRUITING	Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT06948019	PHASE1/PHASE2	NOT_YET_RECRUITING	Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)
NCT06478238	EARLY_PHASE1	RECRUITING	Calcium Folinate Treatment of Spastic Paraplegia 56
NCT00023075	Not specified	COMPLETED	Nuclear Magnetic Spectroscopy Imaging to Evaluate Primary Lateral Sclerosis, Hereditary Spastic Paraplegia and Amyotrophic Lateral Sclerosis
NCT00136630	Not specified	COMPLETED	Natural History, Genetic Bases and Phenotype-genotype Correlations in Autosomal Dominant Spinocerebellar Degenerations
NCT00140829	Not specified	COMPLETED	SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias
NCT00677768	Not specified	COMPLETED	Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
NCT01568658	Not specified	ACTIVE_NOT_RECRUITING	Genetic and Physical Study of Childhood Nerve and Muscle Disorders
NCT02327845	Not specified	ENROLLING_BY_INVITATION	Phenotype, Genotype & Biomarkers in ALS and Related Disorders
NCT02852278	Not specified	COMPLETED	A Patient Centric Motor Neuron Disease Activities of Daily Living Scale
NCT02859428	Not specified	TERMINATED	Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31
NCT03104088	Not specified	COMPLETED	Studying Cognition in SPG4
NCT03206190	Not specified	RECRUITING	The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4
NCT03627416	Not specified	COMPLETED	Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy
NCT03981276	Not specified	RECRUITING	Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
NCT04006418	Not specified	RECRUITING	A Registered Cohort Study on Spastic Paraplegia
NCT04180098	Not specified	COMPLETED	Improving Gait Adaptability in Hereditary Spastic Paraplegia
NCT04256681	Not specified	COMPLETED	SNAP: Measurement of the Subjective Perception of the Symptom in Hereditary Spastic Paraparesis (HSP)
NCT04712812	Not specified	RECRUITING	Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
NCT04875416	Not specified	ACTIVE_NOT_RECRUITING	Phenotype, Genotype and Biomarkers 2
NCT04912609	Not specified	COMPLETED	Trehalose Administration in Subjects With Spastic Paraplegia 11 (3AL-SPG11)
NCT05354622	Not specified	RECRUITING	Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
NCT05373082	Not specified	COMPLETED	Identification of Modifying Factors in Hereditary Spastic Paraplegia
NCT05411627	Not specified	WITHDRAWN	A Pilot Study of Shockwave Therapy in HSP
NCT05432999	Not specified	COMPLETED	Extracorporeal Shockwave Therapy for Spasticity in People With Spinal Cord Injury
NCT05613114	Not specified	COMPLETED	Effect of Dalfampridine in Patients With Hereditary Spastic Paraplegia
NCT05767268	Not specified	COMPLETED	Assessment of the Psychophysical State During Rehabilitation Treatment With Lokomat
NCT05848271	Not specified	RECRUITING	Natural History Study of Patients with HPDL Mutations
NCT06156813	Not specified	RECRUITING	Turkish Lower-Extremity Motor Activity Log (LE-MAL)
NCT06229626	Not specified	RECRUITING	Evaluation of an Intensive Training Program for Patients with Hereditary Spastic Paraparesis SPG4/Spast
NCT06260982	Not specified	UNKNOWN	Cognitive Disorders in Hereditary Spastic Paraplegia Type 4
NCT06553976	Not specified	RECRUITING	Spastic Paraplegia - Centers of Excellence Research Network
NCT06572046	Not specified	RECRUITING	STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies
NCT06573866	Not specified	RECRUITING	Enhancement of Quality of Work And Life
NCT06680063	Not specified	COMPLETED	Correlation Between Clinical Assessment and Neurophysiological Assessment in Spinal Cord Injury